deferoxamine has been researched along with Allergy, Drug in 11 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eight patients with transfusion-dependent thalassemia major were given continuous intravenous infusions of the chelator, deferoxamine mesylate, to reduce iron overload." | 7.68 | Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. ( Freedman, MH; Grisaru, D; MacLusky, I; Olivieri, N; Thorner, PS, 1990) |
| "Thalassemia major is an inherited form of chronic hemolytic anemia that results in iron overload due to regular blood transfusions." | 5.40 | Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine. ( Poachanukoon, O; Satayasai, W; Silapamongkonkul, P; Surapolchai, P, 2014) |
| "Eight patients with transfusion-dependent thalassemia major were given continuous intravenous infusions of the chelator, deferoxamine mesylate, to reduce iron overload." | 3.68 | Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. ( Freedman, MH; Grisaru, D; MacLusky, I; Olivieri, N; Thorner, PS, 1990) |
| "Thalassemia major is an inherited form of chronic hemolytic anemia that results in iron overload due to regular blood transfusions." | 1.40 | Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine. ( Poachanukoon, O; Satayasai, W; Silapamongkonkul, P; Surapolchai, P, 2014) |
| " After that, DFO was further diluted and was restarted with lower dosage and longer infusion period." | 1.33 | Successful desensitization of a case with desferrioxamine hypersensitivity. ( Aydinok, Y; Can, D; Demir, E; Gülen, F; Gulen, H; Tanaç, R; Yenigün, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Surapolchai, P | 1 |
| Poachanukoon, O | 1 |
| Satayasai, W | 1 |
| Silapamongkonkul, P | 1 |
| Gülen, F | 1 |
| Demir, E | 1 |
| Tanaç, R | 1 |
| Aydinok, Y | 1 |
| Gulen, H | 1 |
| Yenigün, A | 1 |
| Can, D | 1 |
| Miller, KB | 1 |
| Rosenwasser, LJ | 1 |
| Bessette, JA | 1 |
| Beer, DJ | 1 |
| Rocklin, RE | 1 |
| Romeo, MA | 2 |
| Di Gregorio, F | 2 |
| Schiliro, G | 1 |
| La Rosa, M | 1 |
| Russo, G | 1 |
| Lombardo, T | 1 |
| Ferro, G | 1 |
| Frontini, V | 1 |
| Percolla, S | 1 |
| Cianciulli, P | 1 |
| Sorrentino, F | 1 |
| Maffei, L | 1 |
| Amadori, S | 1 |
| Mangiagli, A | 1 |
| De Sanctis, V | 1 |
| Campisi, S | 1 |
| Di Silvestro, G | 1 |
| Urso, L | 1 |
| Mey, U | 1 |
| Freedman, MH | 2 |
| Grisaru, D | 1 |
| Olivieri, N | 1 |
| MacLusky, I | 1 |
| Thorner, PS | 1 |
| Bentur, Y | 1 |
| Koren, G | 1 |
2 reviews available for deferoxamine and Allergy, Drug
| Article | Year |
|---|---|
[Foundations of the diagnosis and therapy of hemolytic anemias].
Topics: Agglutinins; Anemia, Hemolytic; Antigens; Autoimmune Diseases; Blood Protein Disorders; Blood Transf | 1978 |
Biological and toxic properties of deferoxamine.
Topics: Cataract; Cell Division; Deferoxamine; DNA; Drug Hypersensitivity; Hearing Disorders; Humans; Pulmon | 1989 |
9 other studies available for deferoxamine and Allergy, Drug
| Article | Year |
|---|---|
Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine.
Topics: Adolescent; Anaphylaxis; beta-Thalassemia; Blood Transfusion; Deferoxamine; Desensitization, Immunol | 2014 |
Successful desensitization of a case with desferrioxamine hypersensitivity.
Topics: beta-Thalassemia; Child; Deferoxamine; Desensitization, Immunologic; Drug Hypersensitivity; Female; | 2006 |
Rapid desensitisation for desferrioxamine anaphylactic reaction.
Topics: Adult; Anaphylaxis; Deferoxamine; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Male | 1981 |
Allergy to desferrioxamine.
Topics: Child; Deferoxamine; Drug Hypersensitivity; Female; Humans; Thalassemia | 1984 |
Desensitization treatment for anaphylactoid reactions to desferrioxamine in a pediatric patient with thalassemia.
Topics: beta-Thalassemia; Child, Preschool; Deferoxamine; Desensitization, Immunologic; Drug Hypersensitivit | 1996 |
High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
Topics: Adolescent; Adult; beta-Thalassemia; Catheters, Indwelling; Chelation Therapy; Deferoxamine; Drug Hy | 1996 |
Continuous low-dose subcutaneous desferrioxamine (DFO) to prevent allergic manifestations in patients with iron overload.
Topics: Adult; Biopsy; Cell Degranulation; Chelating Agents; Deferoxamine; Dose-Response Relationship, Drug; | 1996 |
[Long-term follow-up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity].
Topics: beta-Thalassemia; Deferoxamine; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Infant; Ir | 2000 |
Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Drug Hypersensitivity; Female; Humans; Imm | 1990 |